Tag
Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoint
This study highlights the complementary utility of liver corrected T1 (cT1) and magnetic resonance elastography (MRE) for predicting chronic liver disease progression, emphasizing the critical prognostic role of disease activity beyond fibr
Claudin-1 is upregulated in primary sclerosing cholangitis (PSC), promoting biliary fibrosis and cholestasis. Preclinical models show that Claudin-1-specific monoclonal antibodies reduce liver injury and fibrosis, highlighting a promising t
Hypertension independently worsens clinical outcomes and liver fibrosis progression in MASLD, highlighting the need for integrated cardiovascular and hepatic care.
The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted th
A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.
The HARMONY trial reveals that once-weekly efruxifermin significantly improves liver fibrosis without worsening MASH over 96 weeks, with a favorable safety profile supporting its phase 3 evaluation.
This RCT compares 16:8 intermittent fasting and low-calorie diets in MAFLD patients, revealing both improve liver enzymes and anthropometrics, but low-calorie diet shows superior reduction in liver steatosis, fibrosis, and triglycerides.
HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.
A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.
A twofold rise in advanced liver fibrosis among US heavy drinkers over two decades is linked to increased metabolic syndrome, age, and socioeconomic risk, not higher alcohol intake.
